Evidence map›Paper›PMID 26729752›Full record

ArticleHypertension (Dallas, Tex. : 1979)2016

Sildenafil Treatment Ameliorates the Maternal Syndrome of Preeclampsia and Rescues Fetal Growth in the Dahl Salt-Sensitive Rat.

Ellen E Gillis, Jennifer N Mooney, Michael R Garrett, Joey P Granger, Jennifer M Sasser

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Guidelines for assessing maternal cardiovascular physiology during pregnancy and postpartum.American journal of physiology. Heart and circulatory physiology · 2024
    Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Cardiovascular complications of pregnancy.The Journal of clinical investigation · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ellen E GillisFrom the Departments of Pharmacology and Toxicology (E.E.G., J.N.M., M.R.G., J.M.S.), Medicine (M.R.G.), and Physiology and Biophysics (J.P.G.), University of Mississippi Medical Center, Jackson.
Jennifer N MooneyFrom the Departments of Pharmacology and Toxicology (E.E.G., J.N.M., M.R.G., J.M.S.), Medicine (M.R.G.), and Physiology and Biophysics (J.P.G.), University of Mississippi Medical Center, Jackson.
Michael R GarrettFrom the Departments of Pharmacology and Toxicology (E.E.G., J.N.M., M.R.G., J.M.S.), Medicine (M.R.G.), and Physiology and Biophysics (J.P.G.), University of Mississippi Medical Center, Jackson.
Joey P GrangerFrom the Departments of Pharmacology and Toxicology (E.E.G., J.N.M., M.R.G., J.M.S.), Medicine (M.R.G.), and Physiology and Biophysics (J.P.G.), University of Mississippi Medical Center, Jackson.
Jennifer M SasserFrom the Departments of Pharmacology and Toxicology (E.E.G., J.N.M., M.R.G., J.M.S.), Medicine (M.R.G.), and Physiology and Biophysics (J.P.G.), University of Mississippi Medical Center, Jackson. jsasser@umc.edu.
University of Mississippi Medical Center · US

Funding

The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI TAYLOR, ERIN BASSFORD · 2013 to 2022
$23.4M
Hypertension and Cardiorenal Research Training ProgramT32HL105324 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI Joey P. Granger · 2010 to 2026
$7.8M
Genetics of Renal End Organ Damage in HypertensionR01HL094446 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI GARRETT, MICHAEL R · 2009 to 2013
$1.8M
Mechanisms of Renoprotection by Relaxin in HypertensionK01DK095018 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI SASSER, JENNIFER M · 2012 to 2016
$634k
NHLBI NIH HHS R01 HL094446NHLBI NIH HHS R01HL094446NHLBI NIH HHS T32 HL105324NHLBI NIH HHS T32HL105324NIDDK NIH HHS K01 DK095018NIGMS NIH HHS P20 GM104357NIGMS NIH HHS P20GM104357
6 · The paper itself

Abstract

Preeclampsia, a hypertensive disorder of pregnancy, is detrimental to both mother and fetus. There is currently no effective treatment, but sildenafil, a phosphodiesterase-5 inhibitor, has been proposed as a potential therapy to reduce blood pressure and improve uteroplacental perfusion in preeclamptic patients. We hypothesized that sildenafil would improve the maternal syndrome and fetal outcomes in the Dahl S rat model of superimposed preeclampsia. Dahl S rats were mated, and half received sildenafil (50 mg/kg per day, via food) from day 10 through day 20 of pregnancy. The untreated Dahl S rats had a significant rise in blood pressure and a 2-fold increase in urinary protein excretion from baseline to late pregnancy; however, sildenafil-treated Dahl S rats exhibited ≈40 mm Hg drops in blood pressure with no rise in protein excretion. Sildenafil also increased creatinine clearance and reduced nephrinuria and glomerulomegaly. Sildenafil treatment reduced the uterine artery resistance index during late pregnancy in the Dahl S rat and improved fetal outcomes (survival, weight, and litter size). In addition, 19% of all pups were resorbed in untreated rats, with no incidence of resorptions observed in the treated group. Furthermore, tumor necrosis factor-α, endothelin-1, and oxidative stress, which are characteristically increased in women with preeclampsia and in experimental models of the disease, were reduced in treated rats. These data suggest that sildenafil improves the maternal syndrome of preeclampsia and blood flow to the fetoplacental unit, providing preclinical evidence to support the hypothesis that phosphodiesterase type 5 inhibition may be an important therapeutic target for the treatment of preeclampsia.

Indexed as

Pregnancy, AnimalAnimalsBlood PressureDisease Models, AnimalFemaleFetal DevelopmentPre-EclampsiaPregnancyRatsRats, Inbred DahlSildenafil CitrateSyndromeVascular ResistanceVasodilator AgentsSildenafil CitrateVasodilator Agentsendothelin-1oxidative stressphosphodiesterase-5 inhibitorspregnancytumor necrosis factor-α

Identifiers

PMID26729752
PMCPMC4752413
OpenAlexW2229705898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.